325 related articles for article (PubMed ID: 19502792)
1. Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2.
Burdach S; Plehm S; Unland R; Dirksen U; Borkhardt A; Staege MS; Müller-Tidow C; Richter GH
Cell Cycle; 2009 Jul; 8(13):1991-6. PubMed ID: 19502792
[TBL] [Abstract][Full Text] [Related]
2. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation.
Richter GH; Plehm S; Fasan A; Rössler S; Unland R; Bennani-Baiti IM; Hotfilder M; Löwel D; von Luettichau I; Mossbrugger I; Quintanilla-Martinez L; Kovar H; Staege MS; Müller-Tidow C; Burdach S
Proc Natl Acad Sci U S A; 2009 Mar; 106(13):5324-9. PubMed ID: 19289832
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs.
Svoboda LK; Harris A; Bailey NJ; Schwentner R; Tomazou E; von Levetzow C; Magnuson B; Ljungman M; Kovar H; Lawlor ER
Epigenetics; 2014 Dec; 9(12):1613-25. PubMed ID: 25625846
[TBL] [Abstract][Full Text] [Related]
4. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
5. Relation of neurological marker expression and EWS gene fusion types in MIC2/CD99-positive tumors of the Ewing family.
Amann G; Zoubek A; Salzer-Kuntschik M; Windhager R; Kovar H
Hum Pathol; 1999 Sep; 30(9):1058-64. PubMed ID: 10492040
[TBL] [Abstract][Full Text] [Related]
6. Absence of detectable EWS/FLI1 expression after therapy-induced neural differentiation in Ewing sarcoma.
Knezevich SR; Hendson G; Mathers JA; Carpenter B; Lopez-Terrada D; Brown KL; Sorensen PH
Hum Pathol; 1998 Mar; 29(3):289-94. PubMed ID: 9496833
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
8. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.
Riggi N; Suvà ML; Suvà D; Cironi L; Provero P; Tercier S; Joseph JM; Stehle JC; Baumer K; Kindler V; Stamenkovic I
Cancer Res; 2008 Apr; 68(7):2176-85. PubMed ID: 18381423
[TBL] [Abstract][Full Text] [Related]
9. Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1.
Tomazou EM; Sheffield NC; Schmidl C; Schuster M; Schönegger A; Datlinger P; Kubicek S; Bock C; Kovar H
Cell Rep; 2015 Feb; 10(7):1082-95. PubMed ID: 25704812
[TBL] [Abstract][Full Text] [Related]
10. A model for transmission of the H3K27me3 epigenetic mark.
Hansen KH; Bracken AP; Pasini D; Dietrich N; Gehani SS; Monrad A; Rappsilber J; Lerdrup M; Helin K
Nat Cell Biol; 2008 Nov; 10(11):1291-300. PubMed ID: 18931660
[TBL] [Abstract][Full Text] [Related]
11. Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors.
Li Y; Li X; Fan G; Fukushi J; Matsumoto Y; Iwamoto Y; Zhu Y
Cancer Lett; 2012 Jul; 320(1):14-22. PubMed ID: 22266186
[TBL] [Abstract][Full Text] [Related]
12. EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins.
Gollavilli PN; Pawar A; Wilder-Romans K; Natesan R; Engelke CG; Dommeti VL; Krishnamurthy PM; Nallasivam A; Apel IJ; Xu T; Qin ZS; Feng FY; Asangani IA
Cancer Res; 2018 Aug; 78(16):4760-4773. PubMed ID: 29898995
[TBL] [Abstract][Full Text] [Related]
13. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
Chen H; Tu SW; Hsieh JT
J Biol Chem; 2005 Jun; 280(23):22437-44. PubMed ID: 15817459
[TBL] [Abstract][Full Text] [Related]
15. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
16. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
17. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells.
Du J; Li L; Ou Z; Kong C; Zhang Y; Dong Z; Zhu S; Jiang H; Shao Z; Huang B; Lu J
Breast Cancer Res Treat; 2012 Jan; 131(1):65-73. PubMed ID: 21465172
[TBL] [Abstract][Full Text] [Related]
18. Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue: a comparison of two FISH strategies and RT-PCR in malignant round cell tumors.
Bridge RS; Rajaram V; Dehner LP; Pfeifer JD; Perry A
Mod Pathol; 2006 Jan; 19(1):1-8. PubMed ID: 16258512
[TBL] [Abstract][Full Text] [Related]
19. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.
Prieur A; Tirode F; Cohen P; Delattre O
Mol Cell Biol; 2004 Aug; 24(16):7275-83. PubMed ID: 15282325
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells.
Grimaldi G; Christian M; Steel JH; Henriet P; Poutanen M; Brosens JJ
Mol Endocrinol; 2011 Nov; 25(11):1892-903. PubMed ID: 21903722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]